维普中文期刊产品整合服务
58篇 您的检索式:作者名="HOCHSTER H"
    题名 作者 年代 出处 被引量
1Safety and efficacy of oxaliplatin and fluoropyrimidine regimens with or without bevacizumab as first-line treatment of metastatic colorectal cancer:results of the TREE Study显示文摘HOCHSTER H S HART L L RAMANATHAN R K 2008J Clin Oncol2008,26,21:1
2Preliminary results of a randomized study of aafety and tolerability of three oxaliplatinbased regimens as first-line treatment for advanced colorectal cancer显示文摘Welles L Hochster H Ramanathan R 2004J Clin Oncol2004,2,:1
3Bi- weekly 72-h 9-aminocamptothecin infusion as second-line therapy for ovarian cancinoma : Phase II study of the new york gynecologic oncology group and the eastern cooperative oncology group 显示文摘HOCHSTER H PLIMACK E R RUNOWICZ C D 2004J Clin Oncol2004,22,1:1
4A phase Ⅱ study of recombinant human interleukin-4 for advanced or recurrent non-small cell lung cancer显示文摘 Figlin R Hochster H 1998Cancer J Sci Am1998,4,1:1
5Randomizde phase Ⅱ trial of cetuximab/bevacizumab/irinotecan(CBI)in irinotecan refractory colorectal cancer显示文摘Saltz L Lenz H-J Hochster H 2005J Clin Oncol2005,23,16:1
6Phase I/II dose - escalation study of pemetrexed plus irinotecan in patients with advanced colorectal cancer 显示文摘Hochster H Kettner E Kroning H 2005Clin Colorectal Cancer2005,5,4:1
7VEGF inhibition and renal thrombotic microangiopathy显示文摘Eremina V Jefferson J A Kowalewska J Hochster H Haas M Weisstuch J 2008N Engl J Med2008,358,:1
8Maintenance Rituximab after CVP results in superior clinical outcome in advanced follicular lymphoma(FL) :results of the E1496 phase III trial from the Eastern Cooperative Oncology Group and the Cancer and Leukaemia GroupB 显示文摘Hochster H Weller E Gascoyne R 2005Blood2005,106,:1
9Cetuximab(IMCC225)plus irinotecan(CPT-11)is activeinCPT-11 refractory colorectal cancer(CRC)that expresses epidermal growth factor receptor(EGFR)显示文摘Salts L Rubin M Hochster H 2001Proc Am Sac Clin Oncol2001,20,:1
10Prolonged topotecan infusion with cisplatin in the first-line treatment of ovarian cancer:An NYGOG and ECOG study显示文摘Hochster H S Plimack E R Mandeli J 2006Gynecol Oncol2006,100,2:1
11Randomized phase Ⅱ trial of cetuximab/bevacizumab/irinotecan(CBI)versus cetuximab/bevacizumab(CB)in irinotecan refractory colorectal cancer显示文摘Saltz L Lenz H Hochster H 2005J Clin Oncol2005,23,:1
12Oxaliplatin with weekly bolus fluorouracil and low-dose leucovorin as first line therapy for patients with colorectal cancer显示文摘Hochster H Chachoua A Speyer J 2003J Clin Oncol2003,21,14:1
13Consensus report of the international society of gastrointestinal oncology on therapeutic progress in advanced pancreatic cancer显示文摘Hochster H S Haller D G de Gramont A 2006Cancer2006,107,4:1
14Maintenance rituximab after eyclophosphamide, vincristine, and prednisone prolongs progression free survival in advanced indolent lymphoma: results of the randomized phase III ECOG1496 Study显示文摘Hochster H Weller E Gascoyne RD 2009J Clin Oncol2009,27,10:1
15Increased mortality associated with higher dose cyclophosphamide plus fludarabine in advanced stage indolent lymphoma patients treated on E1496,an ECOG and CALGB study显示文摘 WELLER E KUZAL T 2002Proc Am Soc Clin Oncol2002,21,:1
16Safety and efficacy of oxaliplatin and fluoropyrimidine regimens with or without bevacizumab as first line treatment of metastatic colorec tal cancer: results of the TREE Study显示文摘Hochster H S Hart L L Ramanathan R K 2008J Clin Oncol2008,26,21:1
17Safety and efficacy of oxaliplatin and fluoropyrimidine regimens with or without bevaci- zumab as first- line treatment of metastatic colorectal cancer: results of the TREE Study显示文摘HOCHSTER H S HART L L RAMANATHAN R K 2008J Clin Oncol2008,26,21:1
18Phase Ⅰ/Ⅱ dose-escalation study of pemetrexed plus irinotecan in patients with advanced colorectal cancer显示文摘HOCHSTER H KETTNER E KRONING H 2005Clin Colorectal Cancer2005,5,4:1
19Stop and go: yes or no?显示文摘Hochster H S 2009J Clin Oncol2009,27,34:1
20Phase Ⅰ/Ⅱ doseescalation study of pemetrexed plus irinotecan in patients with advanced colorectal cancer 显示文摘Hochster H Kettner E Kroning H 2005Clin Colorectal Cancer2005,5,4:1
返回顶部 每页显示:
共3页 首页 上一页 第1页 下一页 末页 /3 跳转

网站首页 | 关于我们 | 联系我们 | 产品服务 | 客服中心 | 广告服务 | 版权声明 | 网站联盟 | 友情链接 | 售卡网点

版权所有© 渝B2-20050021-1 渝公网安备 50019002500403号 违法和不良信息举报中心

互联网出版许可证 新出网证(渝)字10号 全国400电话 - 免长途话费